Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus by Evers, Andrea W. M. et al.
Special Article
Psychother Psychosom
Implications of Placebo and Nocebo 
Effects for Clinical Practice: Expert 
Consensus
Andrea W.M. Evers a    Luana Colloca b    Charlotte Blease c    Marco Annoni d    Lauren Y. Atlas e    
Fabrizio Benedetti f    Ulrike Bingel g    Christian Büchel h    Claudia Carvalho i    Ben Colagiuri j    
Alia J. Crum k    Paul Enck l    Jens Gaab m    Andrew L. Geers n    Jeremy Howick o    Karin B. Jensen p    
Irving Kirsch q    Karin Meissner r    Vitaly Napadow s    Kaya J. Peerdeman a    Amir Raz t    
Winfried Rief u    Lene Vase v    Tor D. Wager w    Bruce E. Wampold x, y    Katja Weimer z    
Katja Wiech A    Ted J. Kaptchuk q    Regine Klinger B    John M. Kelley q    
a
 Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, The Netherlands; 
b
 Departments of Pain Translational Symptoms Science and Anaesthesiology, School of Nursing and Medicine, 
University of Maryland Baltimore, Baltimore, MD, USA; c General Medicine and Primary Care, Beth Israel Deaconess 
Medical Center, Boston, MA, USA; d Institute of Biomedical Technologies, National Research Council, Rome, Italy; 
e
 Section on Affective Neuroscience and Pain, NIH, Bethesda, MA, USA; f Physiology and Neuroscience, University 
of Turin Medical School, Turin, Italy; g Department of Neurology, University Hospital Essen, Essen, Germany; 
h
 Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 
i
 Department of Clinical and Health Psychology, Instituto Universitário de Ciências Psicológicas, Lisbon, Portugal; 
j
 School of Psychology, University of Sydney, Sydney, NSW, Australia; k Department of Psychology, Stanford 
University, Stanford, CA, USA; l Department of Psychosomatic Medicine and Psychotherapy, University Hospital 
Tübingen, Tübingen, Germany; m Faculty of Psychology, University of Basel, Basel, Switzerland; n Department 
of Psychology, University of Toledo, Toledo, OH, USA; o Nuffield Department of Primary Care Health Sciences, 
University of Oxford, Oxford, UK; p Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden; 
q
 Beth Israel Deaconess Medical Center, Program in Placebo Studies, Boston, MA, USA; r Division of Health 
Promotion, University of Applied Sciences, Coburg, Germany; s Athinoula A. Martinos Center for Biomedical 
Imaging, Charlestown, MA, USA; t Departments of Psychiatry, Neurology and Neurosurgery, McGill University, 
Montreal, QC, Canada; u Department of Clinical Psychology and Psychotherapy, Philipps University of Marburg, 
Marburg, Germany; v Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark; 
w
 Department of Psychology and Neuroscience, University of Colorado, Boulder, CO, USA; x Department of 
Counseling Psychology, University of Wisconsin-Madison, Madison, WI, USA; y Modum Bad Psychiatric Center, 
Vikersund, Norway; z Clinic for Psychosomatic Medicine and Psychotherapy, University Hospital Ulm, Ulm, Germany; 
A
 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; B Center for Anesthesiology and 
Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Received: March 14, 2018
Accepted after revision: May 22, 2018
Published online: June 12, 2018
Andrea W.M. Evers
Health, Medical and Neuropsychology Unit, Institute of Psychology
Leiden University, PO Box 9555
NL–2300 RB Leiden (The Netherlands)
E-Mail a.evers @ fsw.leidenuniv.nl
© 2018 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/pps
DOI: 10.1159/000490354
Keywords
Placebo effect · Nocebo effect · Patient’s expectancies ·  
Clinical practice · Patient-clinician communication · 
Evidence-based ethical recommendations
Abstract
Background: Placebo and nocebo effects occur in clinical 
or laboratory medical contexts after administration of an 
inert treatment or as part of active treatments and are due 
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to psychobiological mechanisms such as expectancies of 
the patient. Placebo and nocebo studies have evolved 
from predominantly methodological research into a far-
reaching interdisciplinary field that is unravelling the neu-
robiological, behavioural and clinical underpinnings of 
these phenomena in a broad variety of medical conditions. 
As a consequence, there is an increasing demand from 
health professionals to develop expert recommendations 
about evidence-based and ethical use of placebo and no-
cebo effects for clinical practice. Methods: A survey and 
interdisciplinary expert meeting by invitation was orga-
nized as part of the 1st Society for Interdisciplinary Placebo 
Studies (SIPS) conference in 2017. Twenty-nine interna-
tionally recognized placebo researchers participated. Re-
sults: There was consensus that maximizing placebo ef-
fects and minimizing nocebo effects should lead to better 
treatment outcomes with fewer side effects. Experts par-
ticularly agreed on the importance of informing patients 
about placebo and nocebo effects and training health pro-
fessionals in patient-clinician communication to maximize 
placebo and minimize nocebo effects. Conclusions: The 
current paper forms a first step towards developing evi-
dence-based and ethical recommendations about the im-
plications of placebo and nocebo research for medical 
practice, based on the current state of evidence and the 
consensus of experts. Future research might focus on how 
to implement these recommendations, including how to 
optimize conditions for educating patients about placebo 
and nocebo effects and providing training for the imple-
mentation in clinical practice. © 2018 S. Karger AG, Basel
Introduction
Placebo and nocebo research has now evolved from a 
methodological consideration within clinical research to 
a distinct and expanding interdisciplinary field in its own 
right. Placebo studies encompass a broad variety of disci-
plines from biomedicine and neuroscience to the social 
and behavioural sciences and the humanities [1–14]. Pla-
cebo and nocebo effects refer to the beneficial or adverse 
effects that occur in clinical or laboratory medical con-
texts, respectively, after administration of an inert treat-
ment or as part of active treatments, due to mechanisms 
such as expectancies of the patient. Current research in-
corporates both the study of placebo and nocebo respons-
es as an outcome in clinical trials as well as the study of 
placebo and nocebo effects and their psychological and 
neurobiological mechanisms in various clinical applica-
tions, including many medical disciplines. Current objec-
tives in the field are to produce cross-disciplinary concep-
tualizations of placebo and nocebo effects; to re-evaluate 
the ethics of placebos in clinical trials and practice; and to 
initiate the ethical translation of empirical findings into 
clinical practice.
Robust empirical evidence now demonstrates that pla-
cebo and nocebo effects are both significant and measur-
able for many conditions (e.g., pain, depression, Parkin-
son’s disease, fatigue, allergies, and immune deficiencies) 
[1]. Importantly, placebo and nocebo effects can substan-
tially modulate the efficacy and tolerability of active phar-
macological or other medical treatments [15, 16]. This 
empirical evidence from experimental and clinical stud-
ies challenges health-care professionals to translate and 
implement the findings of placebo and nocebo research 
into practice. This translation relates not only to the pos-
sible use of placebos as part of regular treatments (e.g., 
placebo pills) but, far more importantly, to the system-
atic utilization of the mechanisms underlying placebo 
and nocebo effects to augment established treatment 
strategies (e.g., attention to expectations and empathy in 
patient-clinician communication). 
Due to the interdisciplinary nature of this emerging 
field with its potentially wide applications across health 
care, there is a need to develop and formalize guidelines 
on the available evidence, including the possible implica-
tions of placebo and nocebo effects for clinical practice 
[17]. While the American Medical Association (AMA) 
provides explicit guidelines on the clinical use of place-
bos, the General Medical Council (GMC) in the UK pro-
vides no such ethical guidelines [18]. Notwithstanding 
the content of ethical guidelines and codes, studies reveal 
that the use of both pure (e.g., sugar pill) and impure (e.g., 
antibiotics for viral infections) placebos by doctors is 
widespread [19–21]: for example, in the US, 55% of inter-
nists and rheumatologists reported using placebos; in the 
UK, 77% of primary care doctors reported that they used 
placebos at least once per week, while 86% of primary care 
doctors in Denmark admitted that they had used placebos 
at least once within the last year. Surveys aimed at inves-
tigating patients’ attitudes reveal that the majority of re-
spondents believe that placebo use by doctors is accept-
able under certain circumstances [22]. Until now, how-
ever, there has been no study of expert opinions in 
placebo and nocebo studies about the implications of this 
research for clinical practice.
To address this gap, a clinical expert meeting was or-
ganized to survey established placebo researchers’ views 
about placebo and nocebo effects and their translation 
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into clinical practice. The aim of this survey and meeting 
was to develop a consensus on clinical recommendations 
based on the current state of the art in placebo and no-
cebo research among experts in the field. 
Methods
Expert Group
Of the 31 invited speakers at the 1st official Society for Inter-
disciplinary Placebo Studies (SIPS) conference, 29 agreed to take 
part; the 2 who chose not to participate indicated that their re-
search was not clinically focused. The 29 invited experts complet-
ed the survey, of whom 4 invited speakers were unavailable to par-
ticipate due to personal circumstances. A workgroup of 6 members 
(A.W.M.E., L.C., C.B., R.K., T.J.K., and J.M.K.) prepared the sur-
vey and expert meeting. 
The 29 participants were from 12 different countries, had an 
average age of 49.1 years (SD 11.1), and 45% were female. In total, 
65.5% worked clinically (17.2% physicians, 41.4% psychologists, 
and 6.9% acupuncturists). The participants’ backgrounds includ-
ed anaesthesiology, neurology, cognitive neuroscience, primary 
care, internal medicine, psychiatry, psychosomatic medicine, 
health and medical psychology, clinical psychology, epidemiolo-
gy, medical ethics and philosophy. The participants had on aver-
age 14.2 years (SD 8.0) of research experience in the field of pla-
cebo and nocebo studies or related areas since their doctoral de-
gree. 
Survey
Based on a literature review of the relevant empirical evidence 
on possible clinical applications of placebo and nocebo effects, a 
survey was developed that focused on 4 themes: (a) prescription of 
placebo as regular treatment; (b) open-label prescription of pla-
cebo; (c) nocebo effects, and (d) patient-clinician communication. 
Subsequently, items for each theme were developed and checked 
by all members of the workgroup for relevance, readability and 
clarity. This process yielded 40 items in all, 10 for each theme. Par-
ticipants were asked to read each statement and rank it on a 0- to 
10-point scale with 0 meaning “totally disagree” and 10 meaning 
“totally agree.” In addition, participants had the opportunity to 
provide written comments on each item (see online suppl. Appen-
dix Table S1 for a complete overview of the survey; for all online 
suppl. Material, see www.karger.com/doi/10.1159/000490354). 
The survey was analysed by calculating the mean score for each 
item. High agreement with a statement was defined as a mean 
score ≥8, and high disagreement with a statement was defined as 
a mean score ≤2 on the 10-point scale. Items that resulted in more 
mixed levels of agreement (scores between 2 and 8) were not dis-
cussed at the clinical expert meeting. 
Clinical Expert Meeting
The clinical experts met in a 1-day pre-conference session in 
Leiden, The Netherlands, on April 2, 2017. At this meeting, the 
results of the survey and possible recommendations and discus-
sion points were explored in plenary sessions. Consensus was 
reached based upon results of the survey and the discussion during 
the meeting. The meeting was audio-recorded and minutes were 
taken. 
Results
In the sections below, we describe the main results of 
the survey and expert meeting. The initial discussion cen-
tred on defining important components of the placebo 
concept. We then summarize the survey statements with 
high agreement, as well as the related evidence, together 
with relevant comments discussed at the clinical expert 
meeting. A summary of the recommendations is listed in 
Table 1.
Conceptualization of Placebo Effect and Placebo 
Response
The experts agreed that it is crucial to distinguish be-
tween placebo and nocebo responses versus placebo and 
nocebo effects. In line with the drug terminology pro-
posed by Fisher et al. [23] (1965), the placebo and nocebo 
response includes all health changes that result after ad-
ministration of an inactive treatment (i.e., differences in 
symptoms before and after treatment), thus including 
natural history and regression to the mean. The placebo 
and nocebo effect refers to the changes specifically attrib-
utable to placebo and nocebo mechanisms, including the 
neurobiological and psychological mechanisms of expec-
tancies. These mechanisms are shaped, for example, by 
Table 1. Summary of the recommendations formulated by the ex-
pert group
Dos
1 Consider placebo effects as part of regular treatment
2 Inform patients about placebo and nocebo effects in such a 
way that treatment effects are maximized and side effects 
are minimized
3 Ensure a patient-clinician relationship that is characterized 
by trust, warmth and empathy in order to maximize placebo 
effects and minimize nocebo effects
4 Train health-care providers in patient-clinician 
communication to maximize placebo effects and minimize 
nocebo effects
5 Prefer open-label rather than hidden placebo prescription in 
those cases where there is evidence for efficacy and where 
prescribing a placebo is legal
Don’ts
1 Do not take risks (e.g., prescribing invasive treatments) to 
maximize placebo effects
2 Do not consider deception a necessary component of 
placebo effects
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verbal instruction, or nonverbal or situational cues that 
affect treatment expectancies (see communication by the 
SIPS community, July 29, 2016) [see also 24]. Important-
ly, placebos and nocebos not only have effects during the 
prescription of placebo pills, but they can also substan-
tially modulate the efficacy and tolerability of active phar-
macological or other medical treatments. There was 
strong consensus that recommendations should be based 
on the research evidence on placebo and nocebo effects, 
including the involved mechanisms (e.g., expectancies) 
and their consequences for medical practice (e.g., patient-
clinician communication). 
Results of the Survey and Expert Meeting
Considering Placebo Effects as Part of Regular 
Treatment
There was a consensus regarding the importance of 
making optimal use of placebo effects to achieve better 
treatment outcomes (A1) and of optimally informing pa-
tients about placebo effects (A8), for example, to explain 
that a patient might improve due to factors other than the 
treatment itself, such as expectancies regarding treatment 
prognosis. The consensus was based primarily on the 
broad evidence that now exists for placebo and nocebo 
effects on clinical, neurobiological and laboratory out-
comes, at least for the areas of pain, depression, Parkin-
son’s disease, fatigue, allergies and immune deficiency 
[1–14]. However, the experts also acknowledged the cur-
rent lack of knowledge about how best to provide this in-
formation to patients to ensure that patients are optimal-
ly informed. For example, there is insufficient knowledge 
about the ways in which patients and health-care provid-
ers can maximize placebo effects and minimize nocebo 
effects over time during repeated interactions and treat-
ments [25].
The experts strongly agreed that clinicians should not 
prescribe or practice more invasive treatments simply to 
engender more potent placebo effects (A7). Although 
some systematic reviews have found that more intensive 
and invasive treatments can augment placebo effects, re-
sults are not consistent and are often moderated by fac-
tors such as the symptom or condition treated or the spe-
cific procedures used [26]. Moreover, there are clear prac-
tical and ethical restrictions on prescribing more invasive 
treatments for the sake of producing stronger placebo ef-
fects, since these procedures are often more expensive 
and entail a higher risk of undesirable side effects. Con-
sequently, the experts agreed that prescription of more 
intensive and invasive treatment (e.g., injections instead 
of pills) to increase placebo effects is not justified. 
Open-Label Placebo 
Where open-label placebo (i.e., prescription of place-
bo pills with the knowledge and assent of the patient) was 
concerned, there was relatively high consensus that these 
should be preferred to hidden placebos (B3). Important-
ly, there are compelling ethical arguments for informing 
patients about placebo treatments in clinical contexts 
[27]. Related to these findings, the majority of the experts 
strongly agreed that deception is not necessary for pla-
cebo effects to occur (B2). This viewpoint is empirically 
supported by recent studies in patients with irritable bow-
el syndrome and chronic pain, which showed beneficial 
effects of open-label placebo on primary symptom out-
comes, such as pain or disability [28–31]. However, more 
research is needed in other conditions and patient groups 
before recommendations can be developed about their 
possible use in clinical practice. For example, non-signif-
icant findings were found in a pilot study in patients with 
a major depressive disorder in a small sample of 12 pa-
tients, although the medium effect size was comparable 
to the other trials [32–34]. It has to be established wheth-
er specific patient groups or subgroups of patients benefit 
more than others from open-label placebos, or whether 
biological or psychological markers are associated with 
the effectiveness of these open-label placebo strategies. 
Promising is the case of dose-extending placebos (e.g., 
placebo given along with active medication) that mimic 
the psychobiological responses that are associated with 
the effectiveness of the medications with the potential of 
reducing side effects and costs [32]. Although prescrip-
tion of placebos is not yet regulated in any part of the 
world and additional research is necessary on its short- 
and long-term effects, open-label prescription of place-
bos could be considered as a possible future watch and 
wait strategy or for use in long-term conditions when oth-
er treatment options have failed [33].
Nocebo Effects
There was a consensus regarding strategies to mini-
mize and prevent nocebo effects. Experts agreed that no-
cebo effects should be explained to patients (C1) and that 
information about side effects should be presented in 
such a way that nocebo effects are minimized (C4). The 
relatively strong consensus regarding optimally inform-
ing patients to minimize nocebo effects might be due to 
its high clinical relevance, which is based on findings that 
nocebo effects have been shown to consistently worsen 
treatment outcomes and to be at least in part responsible 
for side effects [6, 10–12, 35]. Indeed, there is convincing 
evidence that the way in which patients are informed 
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about risks and side effects influences the likelihood of 
their occurrence. For example, when reassuring words 
are used during a local anaesthetic injection instead of 
emphasizing the pain experience during the procedure, 
pain reports can be reduced [36]. However, there are sev-
eral ethical considerations that are required for optimal 
informed consent of patients, including balancing the 
need for honesty and transparency with the requirement 
that harms should not be induced or increased unneces-
sarily. For example, tailored strategies might be applied 
after the necessary information has been offered, depend-
ing on the patient’s need for more detailed information 
on the risks and side effects of treatment. Such strategies 
might be particularly useful for those patients who have a 
high risk of developing nocebo effects, such as individuals 
who exhibit high levels of somatic amplification or fear of 
side effects [7, 10, 11, 35]. Moreover, evidence is needed 
about the consequences of systematically informing pa-
tients about the role of nocebo effects, for example, by 
introducing the terminology of nocebo effects, or deter-
mining the optimal moment for informing patients about 
nocebo effects during ongoing treatments [37]. 
There was also consensus that clinicians should re-
ceive training and education to minimize nocebo effects 
(C8 and C9). Training and education might include in-
forming health professionals about the negative impact of 
nocebo effects, as well as training them in strategies for 
optimal verbal and non-verbal communication, includ-
ing information about risks and side effects [7, 9–11, 35–
37]. Again, however, there was acknowledgement that 
there has been a lack of research into the education and 
training of health professionals in relation to nocebo ef-
fects. Future studies might focus on evaluating different 
types of educational strategies to obtain insight into the 
most effective tools for training professionals to minimize 
nocebo effects (e.g., how information is communicated) 
as well as into optimal modes of education and training 
(e.g., including virtual reality tools).
Patient-Clinician Communication
The results of the survey showed a high level of agree-
ment regarding patient-clinician communication (4 of 10 
survey items). Experts agreed that a good patient-clini-
cian relationship is essential to make optimal use of pla-
cebo effects to increase therapeutic efficacy (D2). Indeed, 
evidence is mounting that characteristics such as trust, 
warmth, and empathy are helpful in medical communica-
tion to foster placebo effects [38, 39]. In addition, there 
was clear consensus that clinicians should receive regular 
education and training about how to make optimal use of 
placebo effects in their treatments (D6 and D7). However, 
studies examining which elements this training might in-
clude are scarce [17]. For example, a critical point in the 
patient-clinician communication is how to optimize ex-
pectancies without risking subsequent violation of pa-
tient’s expectations and how to avoid eliciting overly pos-
itive expectations that might harm trust in the treatment. 
An important step will be to study specific features of dis-
closures (e.g., content, setting) with the aim of ethically 
tailoring education and training towards maximizing pla-
cebo and minimizing nocebo effects. Finally, experts 
agreed that medical ethics education encompassing pla-
cebo and nocebo effects should be a routine part of clini-
cian training (D8).
Discussion
Intensive research in recent decades provides substan-
tial evidence for the potential benefits of placebo effects, 
as well as the possible harms of nocebo effects [1–14]. In 
this survey of international experts on placebo research, 
there was strong consensus that patients should be in-
formed about placebo and nocebo effects and that health-
care professionals should be trained to maximize placebo 
effects and minimize nocebo effects. The current paper 
forms a first step towards developing evidence-based and 
ethical recommendations about the implications of pla-
cebo and nocebo research for medical practice, based on 
the current state of evidence and the consensus of experts. 
More research is needed in areas such as the prescrip-
tion of open-label placebos, the optimization of interven-
tion strategies to maximize placebo effects and minimize 
nocebo effects, and generalizability across different con-
ditions. For example, it is important to ascertain which 
specific strategies for informing and educating patients 
and health professionals work best, as well as the optimal 
timing for the delivery of these interventions. It is also 
relevant to study the possible additive or interactive ef-
fects of different ways to maximize placebo effects, such 
as optimally informing patients, changing environmental 
cues or using conditioning during medical procedures. 
This might be particularly urgent in the area of nocebo 
effects, for example, for those patients who have a higher 
risk of developing severe adverse events due to high levels 
of fear of side effects or previous traumatic medical pro-
cedures. Large-scale research should also be encouraged 
with the aim to understand the substantial individual dif-
ferences between placebo and nocebo responders and the 
possible neurobiological, psychological and genetic pre-
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dictors. In addition, both condition- and treatment-relat-
ed predictors have to be taken into account (e.g., disease 
severity, length of the treatment) [1–14]. Finally, previous 
evidence for the context dependency of placebo effects 
emphasizes the need for further research into the interac-
tion of stable predictors with situational factors [40]. 
This paper focuses on the possible clinical implications 
of placebo and nocebo effects. However, both placebo 
and nocebo effects as well as responses are key themes for 
further study in health research. For example, the prob-
ability of placebo assignments frequently contributes to 
the placebo response in clinical trials, showing larger ef-
fects in trials with a higher chance of getting the real treat-
ment in comparison to the placebo conditions [2, 3, 41, 
42]. The addition of a hidden or unpredictable prescrip-
tion of the treatment might be a future path to minimize 
these placebo responses in clinical trials [2, 3]. However, 
the development of clinical implications largely depends 
upon research on placebo and nocebo effects, based on 
the understanding of their underlying mechanisms and 
the development of innovative interventions. Important-
ly, these clinical implications involve placebo and nocebo 
effects upon administration of an inert substance or as an 
active treatment, since both are affected by comparable 
mechanisms, such as the patient’s expectancies [1–5]. It 
is also important to emphasize that these recommenda-
tions cannot be generalized in a straightforward manner 
to non-medical contexts, such as psychotherapy [43]. 
Several relevant areas, such as the promising field of phar-
macological conditioning, or predictors of placebo and 
nocebo effects, were omitted from the survey because, so 
far, the relevant evidence is only preliminary [1–14, 44–
46]. Finally, we did not focus on specific determinants of 
placebo and nocebo effects, such as cultural, ethnic, neu-
robiological or personal characteristics of patients, and 
the specific ethical and philosophical concerns that these 
factors raise. 
Placebo and nocebo studies constitute a scientifically 
mature field of interdisciplinary research with applica-
tions in different medical disciplines and conditions. This 
burgeoning research calls for evidence-based recommen-
dations for health professionals in medical practice. The 
initiative of the current survey and expert meeting is an 
important step towards the development of future guide-
lines aimed at helping medical clinicians and other health 
professionals to improve health care in their daily prac-
tice. 
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